AR126393A1 - Terapia combinada para el tratamiento de enfermedades hepáticas - Google Patents

Terapia combinada para el tratamiento de enfermedades hepáticas

Info

Publication number
AR126393A1
AR126393A1 ARP220101774A ARP220101774A AR126393A1 AR 126393 A1 AR126393 A1 AR 126393A1 AR P220101774 A ARP220101774 A AR P220101774A AR P220101774 A ARP220101774 A AR P220101774A AR 126393 A1 AR126393 A1 AR 126393A1
Authority
AR
Argentina
Prior art keywords
treatment
liver diseases
combined therapy
compound
formula
Prior art date
Application number
ARP220101774A
Other languages
English (en)
Inventor
Jinzi Jason Wu
Original Assignee
Gannex Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gannex Pharma Co Ltd filed Critical Gannex Pharma Co Ltd
Publication of AR126393A1 publication Critical patent/AR126393A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica que comprende: una forma del compuesto de la fórmula (I) y al menos un agente terapéutico adicional y, opcionalmente, uno o más portadores farmacéuticamente aceptables. Reivindicación 1: Una combinación farmacéutica que comprende: (1) un compuesto de la fórmula (I) o una salde aquel; y (2) al menos un agente terapéutico adicional.
ARP220101774A 2021-07-06 2022-07-06 Terapia combinada para el tratamiento de enfermedades hepáticas AR126393A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163203038P 2021-07-06 2021-07-06

Publications (1)

Publication Number Publication Date
AR126393A1 true AR126393A1 (es) 2023-10-11

Family

ID=82850288

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101774A AR126393A1 (es) 2021-07-06 2022-07-06 Terapia combinada para el tratamiento de enfermedades hepáticas

Country Status (5)

Country Link
US (1) US20240293385A1 (es)
CN (1) CN117915914A (es)
AR (1) AR126393A1 (es)
TW (1) TWI845975B (es)
WO (1) WO2023280150A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1169312B1 (en) 1999-03-29 2004-10-06 F. Hoffmann-La Roche Ag Glucokinase activators
US20200054589A1 (en) * 2017-02-21 2020-02-20 Genfit Combination of a ppar agonist with a fxr agonist
WO2021108974A1 (en) * 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof
MX2022014238A (es) * 2020-05-13 2023-04-11 Terns Pharmaceuticals Inc Tratamiento combinado de trastornos hepáticos.

Also Published As

Publication number Publication date
CN117915914A (zh) 2024-04-19
TW202317110A (zh) 2023-05-01
WO2023280150A1 (en) 2023-01-12
US20240293385A1 (en) 2024-09-05
TWI845975B (zh) 2024-06-21

Similar Documents

Publication Publication Date Title
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
AR119158A1 (es) Tratamientos de angioedema hereditario
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR119159A1 (es) Tratamientos de angioedema
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PH12020551772A1 (en) Oxo-substituted compound
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
CO2022005926A2 (es) Inhibidores del factor d del complemento para administración oral
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
CL2022000781A1 (es) Tratamientos cognitivos medicinales
AR062779A1 (es) Tratamiento de la esclerosis multiple (em)
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
ECSP12012352A (es) Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2021001349A (es) Un nuevo tratamiento medico para la inflamacion patologica.
AR022348A1 (es) Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
AR117120A1 (es) Terapia de combinación que incluye un inhibidor de krasg¹²c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres